Head and neck cancer: from anatomy to biology
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The 20th century saw great advances in anatomy‐based (surgery and radiotherapy) and chemotherapy approaches for treating head and neck squamous cell carcinoma (HNSCC) and improving quality of life (QoL). However, despite these advances, the survival rate in HNSCC remains at ∼50%. Front‐line treatments often cause severe toxicity and debilitating long‐term impacts on QoL. In recent decades, dramatic advances have been made in our knowledge of fundamental tumor biology and signaling pathways that contribute to oncogenesis and cancer progression. These insights are presenting unprecedented opportunities to develop more effective and less toxic treatments that are specific to particular molecular targets. This review discusses some of the major, potentially targetable, molecular pathways associated with head and neck carcinogenesis. We present the general mechanism underlying the functional components for each signaling pathway, discuss how these components are aberrantly regulated in HNSCC and describe their potential as therapeutic targets. We have restricted our discussion to “drug‐able targets” such as oncogenes including those associated with HPV, tumor hypoxia and microRNAs and present these changes in the context of HNSCC patient care. The specific targeting of these pathways to achieve cancer control/remission and reduce toxicity is now challenging conventional treatment paradigms in HNSCC. This new “biologic era” is transforming our ability to target causal pathways and improve survival outcomes in HNSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“The pathway plays key regulatory roles in cellular processes including cell survival, proliferation and differentiation.(57,75) PI3K is a heterodimeric protein composed of an 85 kD regulatory subunit (p85) and a 110 kD catalytic subunit (p110).”
BackgroundThe human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 1×
“miR-200a targets the zinc-finger-containing transcription factors ZEB1 and ZEB2 that act as transcriptional repressors of E-cadherin and mediate EMT and tumor cell migration.(151,152) Suppression of miR-200a has also been reported in OSCC.”
BackgroundGray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 1×
“Activated cytokine receptors phosphorylate STAT proteins, which dimerize and translocate to the nucleus where they act as transcription factors.(92) JAKs can also activate the Ras-MAPK and PI3K-AKT pathways.”
BackgroundInterdependence of hypoxic and innate immune responses
Nizet, V., & Johnson, R. S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2607 · Cited by 708
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · cited 1×
“However, resistance to EGFR inhibition by cetuximab is a common occurrence.(64) One of the proposed mechanisms of cetuximab resistance is the expression of the tumor-specific EGFR deletion mutant EGFRvIII.”
BackgroundCommon markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650 · cited 1×
“and Progression Aberrant cellular proliferation is a hallmark in cancer(16) and proliferation signatures are present in almost all tumors including HNSCC.(17) Most proliferation-associated genes in cancer are oncogenes and increased expression of these genes provides the rationale for their targeted inhibition.”
BackgroundMicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01977-07 · Cited by 561
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507 · cited 1×
“STAT3 expression is elevated in both cultured HNSCC cells and tumor specimens compared with normal epithelium.(97,98) Increased STAT3 protein levels are an early event in patients with tobacco-mediated HNSCC, with almost no detectable STAT3 in normal tissue.”
BackgroundOvergaard, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.03.004 · Cited by 456
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., Wang, L., Gooding, W. E., Johnson, D. E., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0792 · Cited by 158
Cited by
Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment
Viegas, C., Pereira, D. S. M., & Fonte, P. (2022) · Materials · doi:10.3390/ma15062086 · Cited by 21
“These tumors can range from poorly to well differentiated, and in fact, about 90% of all HNC are squamous cell carcinomas and variants [23,28,38].”
Background
Metadata
- Authors
- Bose, P., Brockton, N. T., & Dort, J. C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2013-03-29
- Volume
- 133
- Issue
- 9
- Pages
- 2013-2023
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1486118213
- Cited by
- 160
- References
- 15
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.